source
- Allen Institute launches multi-hundred-million-dollar effort to turn brain atlas data into neurodegenerative drug candidatesThe Allen Institute, a Seattle nonprofit known for basic brain research, announced a major new effort to move its brain‑atlas knowledge toward drug development. The program will invest several hun…
- Celcuity's gedatolisib trial cuts death risk but misses investor expectationsCelcuity reported data from its Phase 3 VIKTORIA-1 trial evaluating gedatolisib in HR‑positive, HER2‑negative breast cancer with PIK3CA mutations. The trial enrolled 350 patients who had progresse…